Concepedia

Darbie Maccubbin

DM

40

Publications

1.6K

Citations

23

H-Index

1986

Active since

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Roswell Park Comprehensive Cancer Center

Louisville Metabolic and Atherosclerosis Research Center

Grace (United States)

National Clinical Research

Darbie Maccubbin is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacology, and immunology.

Top concepts

Publications per year

1986–2015

40

Publications

40

Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: Efficacy and safety of ezetimibe co-administered with atorvastatin

Evan A. Stein, Steen Stender, Pedro Mata et al. · American Heart Journal · 2004 · 160 citations

, , +8

Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia

Darbie Maccubbin, Harold Bays, Anders Olsson et al. · International Journal of Clinical Practice · 2008 · 113 citations

Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome

Leon A. Simons, Melvin J. Tonkon, L. Masana et al. · Current Medical Research and Opinion · 2004 · 89 citations

MHC-restricted cytotoxic response of chicken T cells: expression, augmentation, and clonal characterization.

Darbie Maccubbin, Louis W. Schierman · The Journal of Immunology · 1986 · 87 citations

Flushing Profile of Extended-Release Niacin/Laropiprant Versus Gradually Titrated Niacin Extended-Release in Patients With Dyslipidemia With and Without Ischemic Cardiovascular Disease

Darbie Maccubbin, Michael J. Koren, Michael Davidson et al. · The American Journal of Cardiology · 2009 · 71 citations

, , +4

Rows per page

1–5 of 40